Report cover image

Global PET Radiopharmaceuticals Industry Growth and Trends Forecast to 2031

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 108 Pages
SKU # APRC20548468

Description

Summary

According to APO Research, The global PET Radiopharmaceuticals market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.

North American market for PET Radiopharmaceuticals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Asia-Pacific market for PET Radiopharmaceuticals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Europe market for PET Radiopharmaceuticals is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

The major global manufacturers of PET Radiopharmaceuticals include Cardinal Health Inc. (U.S.), Bayer AG (Germany), Nordion, Inc. (Canada), Mallinckrodt plc (Ireland), Lantheus Medical Imaging, Inc. (U.S.), IBA Molecular Imaging (Belgium), GE Healthcare (U.K.), Eczacibasi-Monrol Nuclear Products (Turkey) and Bracco Imaging S.p.A (Italy), etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for PET Radiopharmaceuticals, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PET Radiopharmaceuticals.
The PET Radiopharmaceuticals market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global PET Radiopharmaceuticals market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

PET Radiopharmaceuticals Segment by Company

Cardinal Health Inc. (U.S.)
Bayer AG (Germany)
Nordion, Inc. (Canada)
Mallinckrodt plc (Ireland)
Lantheus Medical Imaging, Inc. (U.S.)
IBA Molecular Imaging (Belgium)
GE Healthcare (U.K.)
Eczacibasi-Monrol Nuclear Products (Turkey)
Bracco Imaging S.p.A (Italy)
Advanced Accelerator Applications S.A. (France)
PET Radiopharmaceuticals Segment by Type

F-18
Ru-82
Others
PET Radiopharmaceuticals Segment by Application

Neurology
Cardiology
Oncology
Others
PET Radiopharmaceuticals Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PET Radiopharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of PET Radiopharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PET Radiopharmaceuticals.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of PET Radiopharmaceuticals manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of PET Radiopharmaceuticals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

108 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global PET Radiopharmaceuticals Market Size Estimates and Forecasts (2020-2031)
1.2.2 Global PET Radiopharmaceuticals Sales Estimates and Forecasts (2020-2031)
1.3 PET Radiopharmaceuticals Market by Type
1.3.1 F-18
1.3.2 Ru-82
1.3.3 Others
1.4 Global PET Radiopharmaceuticals Market Size by Type
1.4.1 Global PET Radiopharmaceuticals Market Size Overview by Type (2020-2031)
1.4.2 Global PET Radiopharmaceuticals Historic Market Size Review by Type (2020-2025)
1.4.3 Global PET Radiopharmaceuticals Forecasted Market Size by Type (2026-2031)
1.5 Key Regions Market Size by Type
1.5.1 North America PET Radiopharmaceuticals Sales Breakdown by Type (2020-2025)
1.5.2 Europe PET Radiopharmaceuticals Sales Breakdown by Type (2020-2025)
1.5.3 Asia-Pacific PET Radiopharmaceuticals Sales Breakdown by Type (2020-2025)
1.5.4 South America PET Radiopharmaceuticals Sales Breakdown by Type (2020-2025)
1.5.5 Middle East and Africa PET Radiopharmaceuticals Sales Breakdown by Type (2020-2025)
2 Global Market Dynamics
2.1 PET Radiopharmaceuticals Industry Trends
2.2 PET Radiopharmaceuticals Industry Drivers
2.3 PET Radiopharmaceuticals Industry Opportunities and Challenges
2.4 PET Radiopharmaceuticals Industry Restraints
3 Market Competitive Landscape by Company
3.1 Global Top Players by PET Radiopharmaceuticals Revenue (2020-2025)
3.2 Global Top Players by PET Radiopharmaceuticals Sales (2020-2025)
3.3 Global Top Players by PET Radiopharmaceuticals Price (2020-2025)
3.4 Global PET Radiopharmaceuticals Industry Company Ranking, 2023 VS 2024 VS 2025
3.5 Global PET Radiopharmaceuticals Major Company Production Sites & Headquarters
3.6 Global PET Radiopharmaceuticals Company, Product Type & Application
3.7 Global PET Radiopharmaceuticals Company Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global PET Radiopharmaceuticals Market CR5 and HHI
3.8.2 Global Top 5 and 10 PET Radiopharmaceuticals Players Market Share by Revenue in 2024
3.8.3 2023 PET Radiopharmaceuticals Tier 1, Tier 2, and Tier 3
4 PET Radiopharmaceuticals Regional Status and Outlook
4.1 Global PET Radiopharmaceuticals Market Size and CAGR by Region: 2020 VS 2024 VS 2031
4.2 Global PET Radiopharmaceuticals Historic Market Size by Region
4.2.1 Global PET Radiopharmaceuticals Sales in Volume by Region (2020-2025)
4.2.2 Global PET Radiopharmaceuticals Sales in Value by Region (2020-2025)
4.2.3 Global PET Radiopharmaceuticals Sales (Volume & Value), Price and Gross Margin (2020-2025)
4.3 Global PET Radiopharmaceuticals Forecasted Market Size by Region
4.3.1 Global PET Radiopharmaceuticals Sales in Volume by Region (2026-2031)
4.3.2 Global PET Radiopharmaceuticals Sales in Value by Region (2026-2031)
4.3.3 Global PET Radiopharmaceuticals Sales (Volume & Value), Price and Gross Margin (2026-2031)
5 PET Radiopharmaceuticals by Application
5.1 PET Radiopharmaceuticals Market by Application
5.1.1 Neurology
5.1.2 Cardiology
5.1.3 Oncology
5.1.4 Others
5.2 Global PET Radiopharmaceuticals Market Size by Application
5.2.1 Global PET Radiopharmaceuticals Market Size Overview by Application (2020-2031)
5.2.2 Global PET Radiopharmaceuticals Historic Market Size Review by Application (2020-2025)
5.2.3 Global PET Radiopharmaceuticals Forecasted Market Size by Application (2026-2031)
5.3 Key Regions Market Size by Application
5.3.1 North America PET Radiopharmaceuticals Sales Breakdown by Application (2020-2025)
5.3.2 Europe PET Radiopharmaceuticals Sales Breakdown by Application (2020-2025)
5.3.3 Asia-Pacific PET Radiopharmaceuticals Sales Breakdown by Application (2020-2025)
5.3.4 South America PET Radiopharmaceuticals Sales Breakdown by Application (2020-2025)
5.3.5 Middle East and Africa PET Radiopharmaceuticals Sales Breakdown by Application (2020-2025)
6 Company Profiles
6.1 Cardinal Health Inc. (U.S.)
6.1.1 Cardinal Health Inc. (U.S.) Comapny Information
6.1.2 Cardinal Health Inc. (U.S.) Business Overview
6.1.3 Cardinal Health Inc. (U.S.) PET Radiopharmaceuticals Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Cardinal Health Inc. (U.S.) PET Radiopharmaceuticals Product Portfolio
6.1.5 Cardinal Health Inc. (U.S.) Recent Developments
6.2 Bayer AG (Germany)
6.2.1 Bayer AG (Germany) Comapny Information
6.2.2 Bayer AG (Germany) Business Overview
6.2.3 Bayer AG (Germany) PET Radiopharmaceuticals Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Bayer AG (Germany) PET Radiopharmaceuticals Product Portfolio
6.2.5 Bayer AG (Germany) Recent Developments
6.3 Nordion, Inc. (Canada)
6.3.1 Nordion, Inc. (Canada) Comapny Information
6.3.2 Nordion, Inc. (Canada) Business Overview
6.3.3 Nordion, Inc. (Canada) PET Radiopharmaceuticals Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Nordion, Inc. (Canada) PET Radiopharmaceuticals Product Portfolio
6.3.5 Nordion, Inc. (Canada) Recent Developments
6.4 Mallinckrodt plc (Ireland)
6.4.1 Mallinckrodt plc (Ireland) Comapny Information
6.4.2 Mallinckrodt plc (Ireland) Business Overview
6.4.3 Mallinckrodt plc (Ireland) PET Radiopharmaceuticals Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Mallinckrodt plc (Ireland) PET Radiopharmaceuticals Product Portfolio
6.4.5 Mallinckrodt plc (Ireland) Recent Developments
6.5 Lantheus Medical Imaging, Inc. (U.S.)
6.5.1 Lantheus Medical Imaging, Inc. (U.S.) Comapny Information
6.5.2 Lantheus Medical Imaging, Inc. (U.S.) Business Overview
6.5.3 Lantheus Medical Imaging, Inc. (U.S.) PET Radiopharmaceuticals Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Lantheus Medical Imaging, Inc. (U.S.) PET Radiopharmaceuticals Product Portfolio
6.5.5 Lantheus Medical Imaging, Inc. (U.S.) Recent Developments
6.6 IBA Molecular Imaging (Belgium)
6.6.1 IBA Molecular Imaging (Belgium) Comapny Information
6.6.2 IBA Molecular Imaging (Belgium) Business Overview
6.6.3 IBA Molecular Imaging (Belgium) PET Radiopharmaceuticals Sales, Revenue and Gross Margin (2020-2025)
6.6.4 IBA Molecular Imaging (Belgium) PET Radiopharmaceuticals Product Portfolio
6.6.5 IBA Molecular Imaging (Belgium) Recent Developments
6.7 GE Healthcare (U.K.)
6.7.1 GE Healthcare (U.K.) Comapny Information
6.7.2 GE Healthcare (U.K.) Business Overview
6.7.3 GE Healthcare (U.K.) PET Radiopharmaceuticals Sales, Revenue and Gross Margin (2020-2025)
6.7.4 GE Healthcare (U.K.) PET Radiopharmaceuticals Product Portfolio
6.7.5 GE Healthcare (U.K.) Recent Developments
6.8 Eczacibasi-Monrol Nuclear Products (Turkey)
6.8.1 Eczacibasi-Monrol Nuclear Products (Turkey) Comapny Information
6.8.2 Eczacibasi-Monrol Nuclear Products (Turkey) Business Overview
6.8.3 Eczacibasi-Monrol Nuclear Products (Turkey) PET Radiopharmaceuticals Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Eczacibasi-Monrol Nuclear Products (Turkey) PET Radiopharmaceuticals Product Portfolio
6.8.5 Eczacibasi-Monrol Nuclear Products (Turkey) Recent Developments
6.9 Bracco Imaging S.p.A (Italy)
6.9.1 Bracco Imaging S.p.A (Italy) Comapny Information
6.9.2 Bracco Imaging S.p.A (Italy) Business Overview
6.9.3 Bracco Imaging S.p.A (Italy) PET Radiopharmaceuticals Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Bracco Imaging S.p.A (Italy) PET Radiopharmaceuticals Product Portfolio
6.9.5 Bracco Imaging S.p.A (Italy) Recent Developments
6.10 Advanced Accelerator Applications S.A. (France)
6.10.1 Advanced Accelerator Applications S.A. (France) Comapny Information
6.10.2 Advanced Accelerator Applications S.A. (France) Business Overview
6.10.3 Advanced Accelerator Applications S.A. (France) PET Radiopharmaceuticals Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Advanced Accelerator Applications S.A. (France) PET Radiopharmaceuticals Product Portfolio
6.10.5 Advanced Accelerator Applications S.A. (France) Recent Developments
7 North America by Country
7.1 North America PET Radiopharmaceuticals Sales by Country
7.1.1 North America PET Radiopharmaceuticals Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.1.2 North America PET Radiopharmaceuticals Sales by Country (2020-2025)
7.1.3 North America PET Radiopharmaceuticals Sales Forecast by Country (2026-2031)
7.2 North America PET Radiopharmaceuticals Market Size by Country
7.2.1 North America PET Radiopharmaceuticals Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.2.2 North America PET Radiopharmaceuticals Market Size by Country (2020-2025)
7.2.3 North America PET Radiopharmaceuticals Market Size Forecast by Country (2026-2031)
8 Europe by Country
8.1 Europe PET Radiopharmaceuticals Sales by Country
8.1.1 Europe PET Radiopharmaceuticals Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.1.2 Europe PET Radiopharmaceuticals Sales by Country (2020-2025)
8.1.3 Europe PET Radiopharmaceuticals Sales Forecast by Country (2026-2031)
8.2 Europe PET Radiopharmaceuticals Market Size by Country
8.2.1 Europe PET Radiopharmaceuticals Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.2.2 Europe PET Radiopharmaceuticals Market Size by Country (2020-2025)
8.2.3 Europe PET Radiopharmaceuticals Market Size Forecast by Country (2026-2031)
9 Asia-Pacific by Country
9.1 Asia-Pacific PET Radiopharmaceuticals Sales by Country
9.1.1 Asia-Pacific PET Radiopharmaceuticals Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.1.2 Asia-Pacific PET Radiopharmaceuticals Sales by Country (2020-2025)
9.1.3 Asia-Pacific PET Radiopharmaceuticals Sales Forecast by Country (2026-2031)
9.2 Asia-Pacific PET Radiopharmaceuticals Market Size by Country
9.2.1 Asia-Pacific PET Radiopharmaceuticals Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.2.2 Asia-Pacific PET Radiopharmaceuticals Market Size by Country (2020-2025)
9.2.3 Asia-Pacific PET Radiopharmaceuticals Market Size Forecast by Country (2026-2031)
10 South America by Country
10.1 South America PET Radiopharmaceuticals Sales by Country
10.1.1 South America PET Radiopharmaceuticals Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.1.2 South America PET Radiopharmaceuticals Sales by Country (2020-2025)
10.1.3 South America PET Radiopharmaceuticals Sales Forecast by Country (2026-2031)
10.2 South America PET Radiopharmaceuticals Market Size by Country
10.2.1 South America PET Radiopharmaceuticals Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.2.2 South America PET Radiopharmaceuticals Market Size by Country (2020-2025)
10.2.3 South America PET Radiopharmaceuticals Market Size Forecast by Country (2026-2031)
11 Middle East and Africa by Country
11.1 Middle East and Africa PET Radiopharmaceuticals Sales by Country
11.1.1 Middle East and Africa PET Radiopharmaceuticals Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.1.2 Middle East and Africa PET Radiopharmaceuticals Sales by Country (2020-2025)
11.1.3 Middle East and Africa PET Radiopharmaceuticals Sales Forecast by Country (2026-2031)
11.2 Middle East and Africa PET Radiopharmaceuticals Market Size by Country
11.2.1 Middle East and Africa PET Radiopharmaceuticals Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.2.2 Middle East and Africa PET Radiopharmaceuticals Market Size by Country (2020-2025)
11.2.3 Middle East and Africa PET Radiopharmaceuticals Market Size Forecast by Country (2026-2031)
12 Value Chain and Sales Channels Analysis
12.1 PET Radiopharmaceuticals Value Chain Analysis
12.1.1 PET Radiopharmaceuticals Key Raw Materials
12.1.2 Key Raw Materials Price
12.1.3 Raw Materials Key Suppliers
12.1.4 Manufacturing Cost Structure
12.1.5 PET Radiopharmaceuticals Production Mode & Process
12.2 PET Radiopharmaceuticals Sales Channels Analysis
12.2.1 Direct Comparison with Distribution Share
12.2.2 PET Radiopharmaceuticals Distributors
12.2.3 PET Radiopharmaceuticals Customers
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.